Higher T cell immunoglobulin mucin-3 (Tim-3) expression in cervical cancer is associated with a satisfactory prognosis

BACKGROUND: Cervical cancer (CC), which has been increasing in incidence in recent years, is the fourth most common gynecological cancer in the world. Therapy targeting T cell immunoglobulin mucin-3 (Tim-3), known as the immune checkpoint, has been rapidly developing as oncotherapy for various carci...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yaping, Zhao, Shujun, Zhang, Xinlu, Zhu, Hai, Ji, Xiaorong, Jiang, Yi, Meng, Jie, Shi, Hongyu, Gao, Xiang, Zhang, Xiaoan, Li, Hongyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797693/
https://www.ncbi.nlm.nih.gov/pubmed/35117637
http://dx.doi.org/10.21037/tcr.2020.02.41

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797693/
https://www.ncbi.nlm.nih.gov/pubmed/35117637
http://dx.doi.org/10.21037/tcr.2020.02.41

Ejemplares similares